The nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signal pathway plays an important role in anesthetic and analgesic effects. We sought to determine the involvement of inhibition of soluble guanylyl cyclase (sGC) in the anesthetic mechanism and site of action of volatile anesthetics. We examined the effect of intracerebroventricular (ICV) administration of methylene blue (MB), a sGC inhibitor, on the minimum alveolar anesthetic concentration (MAC) of sevoflurane and the brain cGMP content in rats in vivo. We also investigated the effect of sevoflurane on NO-stimulated sGC activity in vitro. The rats were divided into three groups. After the ICV administration of MB, sevoflurane MAC and brain cGMP contents were measured in the first group and the second group, respectively. In the third group, brain cGMP contents were determined after sevoflurane anesthesia without the ICV administration of MB to examine the direct effect of sevoflurane on brain cGMP contents. MB significantly decreased sevoflurane MAC and brain cGMP content in a dosedependent manner. Sevoflurane itself also dosedependently decreased cGMP contents in brain in vivo and inhibited the NO-stimulated sGC activity in vitro. These results suggest that the inhibition of the NOcGMP signal pathway at the sGC level could be involved in anesthetic or analgesic effects, and the inhibitory effect of sevoflurane on sGC would be one of the sites of action of this anesthetic. Implications: Because the nitric oxide-cyclic guanosine monophosphate signal pathway mediates nociception and the site of action of halogenated volatile anesthetics is uncertain, we examined the possible involvement of inhibition of soluble guanylyl cyclase in the anesthetic mechanism. The inhibitory effect of sevoflurane on soluble guanylyl cyclase could be one of sites of this anesthetic.
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(Anesth Analg 1999;89:484 -9) N itric oxide (NO) is a reactive, free radical gas that is considered a prominent messenger molecule. In the brain, NO is produced by nitric oxide synthase (NOS) in response to the stimulation of excitatory amino acids through N-methyl-d-aspartate (NMDA) and non-NMDA receptors, and it serves as a neurotransmitter or neuromodulator. Although its precise mechanism is uncertain, the NO-cyclic guanosine monophosphate (cGMP) signal pathway may play an important role in anesthetic and analgesic effects. Antagonists at the NMDA receptor have anesthetic and analgesic properties (1, 2) , and the administration of specific inhibitors of NOS reduces the minimum alveolar anesthetic concentration (MAC) of volatile anesthetics (VA) (3, 4) . Conversely, VA were reported to decrease the activity of NMDA receptor (5) and NOS (6) .
The primary receptor for NO, soluble guanylyl cyclase (sGC), is a ferrous heme-containing enzyme. The interaction of NO with ferrous iron results in an alteration of the planar heme structure, producing activation of this enzyme with subsequent production of cGMP (7) .
Because of their halogen content, VA are also attracted to ferrous iron-containing heme proteins. There is a strong similarity between VA and NO in terms of their great affinity for ferrous iron. Thus, it would be logical to anticipate that VA compete with NO at the ferrous iron heme of sGC. We previously reported competition between VA and NO at ferrous iron of sGC and the inhibition of this enzyme by VA in rat soluble fraction (8) .
We undertook this study to identify whether the inhibition of sGC could be implicated in anesthetic and analgesic effects and to examine whether the competition between VA and NO at sGC in the brain was involved in their anesthetic mechanisms. To evaluate this in vivo, we examined the effect of an intracerebroventricular (ICV) administration of methylene blue (MB), a sGC inhibitor, on the MAC of sevoflurane and the brain cGMP content in rats. In vitro, we also determined the effect of sevoflurane on NO-stimulated sGC activity in rat brain soluble fraction.
Methods
The study was approved by our institutional committee on animal research.
In Vivo
The rats were divided into three groups as follows. In the first group, we measured sevoflurane MAC with the ICV administration of MB. In the second group, we measured cGMP contents in the brain with the ICV administration of MB without sevoflurane anesthesia. In the third group, we measured cGMP contents in the brain without the ICV administration of MB with sevoflurane anesthesia.
Twenty-four hours before measuring MAC, male Sprague-Dawley rats (7 wk old, 200 -250 g) were anesthetized with intraperitoneal thiopental (50 mg/kg). A fine, stainless steel, L-shaped tube was implanted into the right lateral ventricle and secured to the skull with strong adhesive. A silicone tube 0.3 mm in inner diameter was connected to one end of this tube, tunneled through the cervical subcutaneous region, and fixed.
MAC of sevoflurane was measured basically according to the methods of Eger (9) . Each rat was placed in an individual plastic chamber (30 cm long and 5 cm in diameter) and was given sevoflurane in oxygen (4 L/min total gas flow). Expired gas was continuously sampled, and the anesthetic concentration was monitored by using an infrared analyzer (Datex, Helsinki, Finland). The rectal temperature was measured and maintained at 36.5-37.5°C with a electric heating mat. After initial equilibration (2.5% sevoflurane 60 min), a tail clamp was applied for 1 min using a long hemostat, and movement in response to the stimulation was observed. The concentration of sevoflurane was increased or decreased by 0.2%-0.3% steps with 20 min of equilibration time allowed after changes in concentration. The response to a noxious stimulus was tested at each concentration. The mean of the lowest concentration without stimulus-evoked movement and the highest concentration with movement was taken as MAC. After measuring baseline MAC, ICV administration was conducted using a volume of 25 L. The MAC was measured again 30 min after the ICV injection.
After killing the rats by head-focused microwave irradiation, the brain was excised and immediately frozen in liquid nitrogen. The frozen tissue was homogenized with 6% trichloroacetic acid, yielding a 10% homogenate, and centrifuged at 2000g for 20 min. The supernatants were washed four times with watersaturated diethyl ether, and cGMP was determined by using an enzyme immunoassay in aliquots of the washed supernatant. The pellet was dissolved with 1 N NaOH, and the protein concentration was measured according to the method of Lowry et al. (10) .
Absence of change in Pao 2 , Paco 2 , and pH was confirmed with blood gas analysis by sampling of arterial blood from the abdominal aorta after the second measurement of MAC.
In Vitro
Male Sprague-Dawley rats (7 wk old, 150 -200 g) were anesthetized with intraperitoneal thiopental (50 mg/ kg). After in situ transcardial perfusion, the brain was excised and homogenated. The homogenate was ultracentrifuged for 60 min at 105,000g. The resultant supernatant was used as the brain soluble fraction.
The NO solution was prepared by equilibrating 10 mL of pure NO gas and 95 mL of extensively deoxygenated water as described by Moy et al. (11) . The concentration of NO in this saturated solution was reported to average 2.4 Ϯ 0.1 mM (12) . sGC activity was determined by measuring the production of cGMP. The incubation was performed for 5 min at 37°C using total volume 600 L with 50 mM Tris, 5 mM MgCl 2 , 1 mM DL-dithiothreitol, 1 mM isobutylmethlxanthine, 0.1 mM guanosine triphosphate, the indicated concentration of sevoflurane, and 0.1 mg of protein of brain soluble fraction. The preincubation was performed for 3 min at 37°C before GTP and the NO solution were added. The reaction was stopped by adding 100 L of 10% trichloroacetic acid and cooling on ice. After centrifugation for 10 min at 2500g, cGMP production was determined by using an enzyme immunoassay in aliquots of the supernatant.
A cGMP enzyme immunoassay kit (RPN 226) was obtained from Amersham Life Sciences (Arlington Heights, IL). Sevoflurane was kindly provided by Nippon Hoechst Marion Roussel (Tokyo, Japan). NO gas was purchased from Yamato-Sanki (Tokyo, Japan). Other chemicals were obtained from Sigma Chemical (St. Louis, MO).
The data were analyzed by using analysis of variance with subsequent intragroup comparisons made by using Scheffé's F-test. A value of P Ͻ 0.05 was considered significant.
Results

In Vivo
The ICV administration of 1, 5, and 25 g/rat MB dose-dependently reduced the MAC of sevoflurane.
The reduction of the MAC by MB was significant at 5 and 25 g/rat and reached a plateau at 5 g/rat. Before the ICV administration, the MACs of sevoflurane (baseline MAC) were not different in each MB concentration group (Figure 1) . Similar to the effect on MAC, MB decreased the brain cGMP contents in a dose-dependent manner, and the inhibitory effects of MB on the brain cGMP contents were significant at 5 and 25 g/rat (Figure 2) . As shown in Figure 3 , the brain cGMP contents were also dose-dependently attenuated by sevoflurane anesthesia itself. Significant differences were obtained at 0.75%, 1.5%, and 3%, compared with 0%. There was no significant difference in the blood gas analysis data among the groups. None of the rats displayed hypoxia, hypercapnia, or acidosis (data not shown).
In Vitro NO (2 ϫ 10 Ϫ8 M) clearly stimulated sGC activity, and sevoflurane dose-dependently inhibited this activity. The inhibitory effect of sevoflurane was significant at 0.812 and 1.165 mM (Figure 4 ).
Discussion
The data in this study show that MB clearly decreased both the MAC of sevoflurane and the brain cGMP content. Sevoflurane itself significantly decreased the brain cGMP content in vivo and attenuated NOstimulated sGC activity in a dose-dependent manner in vitro. These results suggest the possible involvement of an inhibition of NO-cGMP signal pathway at sGC in anesthetic and analgesic effects. Furthermore, the inhibitory effect of sevoflurane on sCG in the brain could be implicated in one of the mechanisms and sites of action of this anesthetic.
There have been several reports that the anesthetic action of general anesthetics are, at least in part, due to the inhibition of the NO-cGMP signaling pathway. A number of anesthetics have an inhibitory effect on the NO-cGMP signaling pathway, and the potent inhibitors of this pathway exhibit an anesthetic action. Isoflurane (5) decreases the activity of NMDA receptor stimulated by NMDA. Competitive (1) and noncompetitive (2) antagonists at NMDA receptors have anesthetic and analgesic properties. At the level of NOS, halothane and isoflurane inhibit the activity of NOS isolated from rat brain (6) . Conversely, the nonselective NOS inhibitor N G -nitro-L-arginine-methyl ester (L-NAME) and the recently identified neuroselective NOS inhibitor 7-nitro indazol (7-NI) decrease the MAC of halothane (3), isoflurane (4) and sevoflurane (13) . We report another association between anesthetic action and the NO-cGMP pathway by demonstrating that sevoflurane attenuated sGC activity and that MB, a sGC inhibitor, reduced the MAC of sevoflurane.
Kawabata et al. (14) showed that the ICV administration of MB and L-NAME produced antinociception in the tail flick test in mice. Because ICV dibutylyl cGMP reverses the effect of both drugs, Kawabata et al. suggested the involvement of cGMP production by sGC in physiological nociceptive processing at a supraspinal level. Two other studies from the same group also reported that the ICV (15) and intrathecal (16) administration of NOC-18, a NO-releasing compound, induces a curtailment of the tail flick latency in the rat, whereas MB causes prolongation of that latency. The ICV, but not intrathecal, administration of MB blocks NOC-induced hyperalgesia. These results indicate that the NOcGMP signal pathway is involved in thermal hyperalgesia in the brain, whereas, in the spinal cord, there may be another pathway in addition to the NO-cGMP signal pathway. In any case, the NOcGMP pathway could play an important role in nociceptive processing, and the inhibition of sGC by MB in the brain produce antinociception. These findings are quite consistent with our data.
The interactions between VA and NO at sGC have been reported in different tissues (5, 8, 17, 18) . These results are not uniform and are controversial. However, the competition between VA and NO could be predicted at the NO binding site in sGC. sGC, a ferrous hemecontaining enzyme, is predominantly activated by nitrosation of the ferrous iron atom, as proposed by Ignarro et al. (19) . Thus, the essential component seems to be the reduced iron atom through which NO can form a coordinate bond. A great affinity of NO for the ferrous iron heme protein is demonstrated by the ease of its binding to other proteins, such as hemoglobin, myoglobin (20) , and cytochrome P-450 (21) . VA are also strongly attracted to the ferrous heme protein because halogens have extremely high electron affinities. VA are not only attracted to ferrous iron, but also are metabolized by them. Cytochrome P-450, hemoglobin, and hemin (22) metabolize VA when iron is in the ferrous state. Therefore, VA show an affinity for ferrous iron of sGC and should interact with NO. In the present study, sevoflurane inhibited NO-stimulated sGC activity in vitro, presumably via this process. The cGMP content in the brain was also decreased by sevoflurane anesthesia itself in vivo. This decrease in cGMP content could reflect the total inhibitory effect of sevoflurane on the NO-cGMP signal pathway, i.e., release of glutamate (presynaptic action), glutamate receptors (NMDA and non-NMDA), NOS, and sGC. However, in vitro, sevoflurane attenuated the NO-stimulated sGC activity. Therefore, the decreased cGMP contents in vivo would be due, at least in part, to the inhibitory effect of sevoflurane on sGC. In addition, the ICV administration of MB reduced the MAC of sevoflurane. We propose that the attenuation of sGC activity by sevoflurane is one of the mechanisms of this anesthetic.
Terasako et al. (5) and Zuo et al. (18) reported that halothane, isoflurane, and enflurane do not affect the sGC activity, which is in contrast with our results. The exact reason for this discrepancy is not apparent, but the different results may arise from the different experimental methods. Terasako et al. (5) stimulated sGC with a maximal dose of sodium nitroprusside and examined the effect of VA at a single concentration. Therefore, this concentration of VA may fail to inhibit sGC activity that was stimulated by a large amount of NO. In the study by Zuo et al. (18), sGC was not equilibrated with VA before the addition of NO. The anesthetics may need a longer time to exert their effects on sGC because of their lower affinity compared with NO. The anesthetic-induced inhibition of sGC would not be observed when NO and anesthetics were added simultaneously, followed by a short incubation, as pointed out by Jing et al. (23) .
In the past five years, much of the work on mechanisms and sites of action of inhaled anesthetics with the production of MAC have focused on the spinal cord, not the brain (24) . However, descending modulatory systems exist and may influence anesthetic action on the cord (25) . The part of MB that was administered ICV could have spread to the cord through the cerebrospinal fluid and exerted its effect in the present study. The effect of ICV administration of MB on both the brain and spinal cord might be different from that of intrathecal MB and may decrease the MAC of sevoflurane. In addition, we measured cGMP content in the brain. Because the analgesic effect of anesthetics is mainly regulated in the spinal cord, cGMP in the spinal cord would have important roles. At doses that do not produce unconsciousness, VA are apparently antalgesic or neutral but not analgesic. However, we demonstrated that sevoflurane 0.75%, which is not enough to render unconsciousness, decreased cGMP content in the brain. Further investigation, such as measurement of cGMP in the spinal cord at a wide range of anesthetic concentrations, will add important information regarding the analgesic effects of VA.
When the NO-cGMP signal pathway is chronically inhibited, there may be no correlation between the MAC of VA and the cGMP content in the brain. Adachi et al. (26) demonstrated that the intraperitoneal injection of L-NAME for four days significantly decreased the cerebellar NOS activity and cGMP level in the rat. However, the value of the halothane MAC was not significantly affected by L-NAME. Thus, they conclude that the anesthetic potency (MAC) of halothane would not be related to brain NOS activity or cGMP levels. Four-day treatments with 7-NI also time-dependently decrease cerebellar cGMP levels, but sevoflurane MAC was reduced for only two days and returned to baseline after three days. Acute treatment by 7-NI, however, dosedependently decreases both sevoflurane MAC and cerebellar cGMP levels (13) . These results suggest that the MAC-reducing effects of 7-NI may not be mediated via the sGC-cGMP system or that there are cGMPindependent compensatory mechanisms that mediate nociception during long-term NOS inhibition. Because the perception of pain and the maintenance of consciousness are vitally important for protecting all life forms, multiple mechanisms seem to coexist to mediate these processes, as proposed by Ichinose et al. (27) . If the NO-cGMP signal pathway is inhibited chronically, other mechanisms may be activated or may take over to mediate nociceptive processing; consequently, the correlation between the MAC of VA and cGMP content in the brain may disappear. We did not examine the effect of chronic treatment of MB, but the acute action of MB on sGC suggests an anesthetic effect.
In conclusion, the inhibition of the NO-cGMP signal pathway at sGC reduced the MAC of sevoflurane, and sevoflurane itself inhibited the sGC activity in the brain. Although many complicated mechanisms are involved in anesthetic action, the inhibitory effect of sevoflurane on sGC must be at least a part of the mechanism and site of action of this anesthetic.
We thank Dr. Salim Hayek (Case Western Reserve University, Cleveland, OH) for his expert manuscript preparation.
